If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
FORTEO® (teriparatide) was approved by the FDA on November 26, 2002.
Teriparatide is indicated for
the treatment of postmenopausal women with osteoporosis at high risk for fracture
increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, and
treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture (Forteo Package Insert, 2012).
Regarding teriparatide’s indication for treatment of post menopausal women with osteoporosis at high risk for fracture, high risk for fracture is defined as
a history of osteoporotic fracture
multiple risk factors for fracture, or
patients who have failed or are intolerant to other available osteoporosis therapy (Forteo Package Insert, 2012).
In postmenopausal women with osteoporosis, teriparatide reduces the risk of vertebral and nonvertebral fractures (Forteo Package Insert, 2012).
FORTEO [package insert]. Indianapolis, IN: Eli Lilly and Company; 2012.
Date of Last Review: September 13, 2017